Curenetics raises £161k for AI-driven immunotherapy prediction platform

Predicting cancer patient response to immunotherapy is the focus of Curenetics Ltd, a London-based software development firm that has just secured £161.1k in new funding. This capital injection values the company at an estimated £8.5m. The business develops a platform that analyses multimodal clinical, genomic, and imaging data to help clinicians and researchers select personalized treatments.

Incorporated in 2018, the company aims to integrate its technology into healthcare systems to improve survival rates and reduce costs. Financial accounts for the year ending 30 April 2025 reported a headcount of four employees. However, recent data from LinkedIn suggests the workforce has grown to 17 staff members, including a team of clinicians, AI engineers, and scientists specializing in oncology, medical technology, and machine learning.

The latest investment follows £50k raised across 2025. Formal documentation regarding this round was filed in June 2026, relating to an allotment of shares that took place in August 2025.